Compare TMP & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TMP | MNKD |
|---|---|---|
| Founded | 1836 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 1996 | 2004 |
| Metric | TMP | MNKD |
|---|---|---|
| Price | $97.79 | $4.05 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $87.00 | $8.69 |
| AVG Volume (30 Days) | 77.6K | ★ 3.7M |
| Earning Date | 04-24-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.21% | N/A |
| EPS Growth | ★ 126.16 | N/A |
| EPS | ★ 3.86 | N/A |
| Revenue | $75,742,000.00 | ★ $348,966,000.00 |
| Revenue This Year | N/A | $35.81 |
| Revenue Next Year | $7.94 | $11.89 |
| P/E Ratio | $25.27 | ★ N/A |
| Revenue Growth | N/A | ★ 22.23 |
| 52 Week Low | $61.88 | $2.23 |
| 52 Week High | $102.59 | $6.51 |
| Indicator | TMP | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 49.81 | 51.16 |
| Support Level | $96.56 | $3.74 |
| Resistance Level | $102.30 | $4.23 |
| Average True Range (ATR) | 2.05 | 0.16 |
| MACD | -0.45 | -0.01 |
| Stochastic Oscillator | 35.47 | 50.70 |
Tompkins Financial Corp is a Financial Holding Company. The company manages its operations through two business segments, consisting of banking and wealth management. It offers various products and services, including commercial and consumer banking, leasing, trust and investment management, financial planning and wealth management, and insurance. Wealth management activities include the results of the company's trust, financial planning, and wealth management services. The company generates the majority of its revenue from the Banking segment.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.